New pill could delay breast cancer worsening in advanced cases
Disease control
Recruiting now
This study compares a new oral drug, D-0502, to a standard injected drug (fulvestrant) in 640 people with a common type of advanced breast cancer (ER-positive, HER2-negative). Participants must have already tried hormone therapy. The main goal is to see if D-0502 can delay cancer…
Phase: PHASE3 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated May 01, 2026 15:57 UTC